Market Intelligence, Clinical Progress, and High-Purity Reagents for Hypercalcemia of Malignancy & Bone Metastasis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PTHLH (PTHrP) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-length) | PTHLH Recombinant Protein (1-141) – High purity (>95%), Endotoxin <1EU/ug, Sequence Verified, N-terminal domain integrity confirmed by Mass Spec. | View PTHLH Products |
| Gene Delivery | PTHLH Promise-ORF / Lentivirus – Full-length ORF for stable cell lines. | View PTHLH Products |
| Receptor Cell System | PTH1R Lentivirus Premade Particles – For stable GPCR-expressing cell line construction (HEK293 background), calcium flux validated. | View PTH1R Products |
| Benchmark Ab | Anti-PTHLH Neutralizing Antibody (Human IgG1) – Positive control for HCM model validation. | View PTHLH Products |
| Validator | PTHLH siRNA Set – For target-specific knockdown verification. | View PTHLH Products |
| Related Ligand (Receptor) | PTH1R – Primary GPCR for PTHLH signaling and analog screening. | View PTH1R Products |
| Related Ligand (Pathway) | RANKL (TNFSF11) – Downstream driver of osteoclast activation in bone metastasis. | View TNFSF11 Products |
| Related Ligand (Selectivity Control) | PTH Recombinant Protein – Competitive binding control for PTH1R selectivity assays. | View PTH Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Active Domain Instability | Precisely truncated N-terminal bioactive fragments (1-36) with theoretical MW verified by Mass Spec. |
| PTH1R vs PTH2R Selectivity | High-purity PTHLH (1-36) and PTH proteins with verified N-terminal integrity for competitive binding assays. |
| Cross-species (Cyno/Mouse/Human) Evaluation | Ortholog protein panel (Human, Mouse, Cyno PTHLH) with >95% purity, sequence verified by Mass Spec. |
| GPCR Cell-based Functional Assay | PTH1R Lentivirus for stable HEK293 cell line; preserves native conformation for calcium flux and cAMP accumulation assays. |
| Lack of Neutralizing Controls | Clinical-grade benchmark antibodies with documented HCM model efficacy. |
| False Positive Binding | Validated siRNA sets for target specificity confirmation in paracrine signaling studies. |
Live PTHLH R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials for Hypercalcemia of Malignancy
- Latest Bone Metastasis Research
- Recent Patent Filings for PTHrP Inhibitors
Global Clinical Landscape & Future Outlook
The race for PTHLH-targeted therapeutics is intensifying, with major players shifting focus from broad-spectrum bisphosphonates and traditional neutralizing mAbs to selective paracrine signaling inhibitors and peptide analogs designed to fine-tune PTH1R activation. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective receptor conformation modulation for osteoporosis without inducing hypercalcemia. Key emerging trends include antibody-mediated PTHrP blockade for breast and lung cancer bone metastasis, N-terminal domain selective inhibitors that preserve physiological cartilage functions, and combination strategies with anti-RANKL and anti-PTHrP dual blockade.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Bristol-Myers Squibb (historical), Emerging Biotechs | Humoral Hypercalcemia of Malignancy (HCM) | PTH1R Competitive Binding Assay (Need high-purity PTHLH N-terminal domain) |
| Peptide Analogs/Antagonists | Radius Health, Academic/Preclinical | Osteoporosis, Bone Metastasis | Receptor Activation/Selectivity Assay (Need high-purity WT PTHLH and PTH vs PTHLH protein pair) |
| Bispecific (anti-PTHrP/RANKL) | Preclinical Development | Solid Tumor Bone Metastasis | Dual Target Engagement (Need PTHLH + RANKL protein combination) |
| Small Molecule (Receptor Antagonist) | Chugai, Preclinical | Hypercalcemia, Hyperparathyroidism | GPCR Cell-based Assay (Need PTH1R Lentivirus stable line) |
Molecular Characteristics & Key Mutations
PTHLH (Parathyroid Hormone-related Protein) is a secreted, multifunctional cytokine (139-177 aa depending on isoform) with critical roles in endochondral bone formation and pathological osteolysis. Unlike membrane-bound targets, PTHLH functions as a paracrine ligand requiring precise N-terminal domain integrity (aa 1-36) for PTH1R activation.
Critical Assay Considerations:
- Species Cross-Reactivity: Therapeutic antibodies must distinguish between human PTHLH and endogenous rodent/primate PTHrP. Our ortholog panel enables preclinical species selection.
- Receptor Selectivity: PTHLH shares PTH1R with PTH; selectivity profiling requires both ligands in head-to-head competition assays.
- Functional Cell Systems: PTH1R is a Class B GPCR requiring cell-based readouts (cAMP/Ca2+). Lentivirus-mediated stable expression ensures consistent receptor density for antagonist screening.
Known Mutations:
- rs267606986 (BDE2 domain): A naturally occurring variant in the BDE2 region of PTHLH.
- rs267606985 (BDE2 domain): Another variant in the BDE2 region.
- A somatic mutation identified in a breast cancer sample (UniProt P12272 VAR_036433). These mutations may impact PTHLH stability, receptor binding, or tumor microenvironment interactions, and should be considered in assay design and drug screening.